B+
Bull case
25%
Probability
Target price
$18.00
+65.7% vs current
KURA
Kura OncologyBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$11.00
+1.3% vs current
B-
Bear case
25%
Probability
Target price
$6.00
-44.8% vs current
AI sentiment snapshot
Latest data as of 2026-06-18
Recent news sentiment (30D)
+58.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+51.8
Score
AI commentary
Primary-source evidence remains constructive, but the name still reads more like a cautious monitoring setup than a clean momentum long. The best new signal is the June 11 combination-data update, while the May quarter confirmed real but still early commercial traction. With low coverage, sparse recent news flow, and a negative deterministic prior on forward returns, conviction should stay moderate until either commercial durability or registrational AML progress is clearer.
RankAlpha Sentiment Codex - 2026-06-18
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-11eventUpdated KOMET-007 combination data strengthened the frontline AML narrativeHigh impact
Kura and Kyowa Kirin reported encouraging longer-term KOMET-007 results in newly diagnosed AML, including 12-month overall survival of 94% in NPM1-m AML and 71% in KMT2A-r AML, with high remission and MRD-negativity rates; if investors treat the durability as supportive of registrational execution, this is the clearest near-term pipeline positive. [#PR-EARNINGS-2026-06-11]
2026-12-31catalystEarly KOMZIFTI launch traction needs to convert into durable commercial uptakeHigh impact
First-quarter 2026 results showed $5.8 million of net product revenue in the first full commercial quarter, 85 new patient starts, 157 total prescriptions, and payer coverage above 93% across more than 12 million lives. That supports the launch case, but the stock likely needs several more quarters of repeatable uptake to rerate on commercialization rather than only pipeline optionality. [#SEC-8K-2026-05-12]
2026-12-31catalystRunway appears sufficient to reach key AML readouts, lowering near-term financing pressureMedium impact
Management said $580.8 million in cash, cash equivalents and short-term investments, plus $180 million in anticipated collaboration payments, should support the ziftomenib AML program through first topline KOMET-017 Phase 3 results. That reduces immediate dilution pressure, though execution still depends on clinical timelines and collaboration cash arriving as expected. [#SEC-8K-2026-05-12]
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-18 • Updated nightlySource: Internal modelMethodology